JP2986966B2 - Melanin production inhibitor - Google Patents
Melanin production inhibitorInfo
- Publication number
- JP2986966B2 JP2986966B2 JP3181832A JP18183291A JP2986966B2 JP 2986966 B2 JP2986966 B2 JP 2986966B2 JP 3181832 A JP3181832 A JP 3181832A JP 18183291 A JP18183291 A JP 18183291A JP 2986966 B2 JP2986966 B2 JP 2986966B2
- Authority
- JP
- Japan
- Prior art keywords
- esculin
- melanin production
- present
- melanin
- production inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000008099 melanin synthesis Effects 0.000 title claims description 19
- 239000003112 inhibitor Substances 0.000 title claims description 9
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims description 36
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 claims description 36
- 229940093496 esculin Drugs 0.000 claims description 36
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 claims description 36
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 claims description 36
- 239000002537 cosmetic Substances 0.000 claims description 17
- 230000002087 whitening effect Effects 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 208000012641 Pigmentation disease Diseases 0.000 description 12
- 230000019612 pigmentation Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 235000020721 horse chestnut extract Nutrition 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000004694 pigment cell Anatomy 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 235000010382 gamma-tocopherol Nutrition 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002478 γ-tocopherol Substances 0.000 description 5
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 229940067596 butylparaben Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- -1 packs Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- HIPQTCQUXOFTFI-UHFFFAOYSA-N 2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)C(=O)C1=CC=CC=C1 HIPQTCQUXOFTFI-UHFFFAOYSA-N 0.000 description 1
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 1
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- BPGXFADACRWNJC-HVDRVSQOSA-N C(CCCCCCCCCCCCCCC)(=O)O.N1[C@@H](CCC1=O)C(=O)O Chemical compound C(CCCCCCCCCCCCCCC)(=O)O.N1[C@@H](CCC1=O)C(=O)O BPGXFADACRWNJC-HVDRVSQOSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000024181 negative regulation of developmental pigmentation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明はメラニン生成抑制剤及び
美白化粧料に関し、詳しくは生きた色素細胞(メラノサ
イト)のメラニン形成系に直接作用してメラニン生成を
抑制するメラニン生成抑制剤、および保存時あるいは使
用時の安定性が良好で皮膚色素沈着症の予防および改善
に優れた美白化粧料を提供せんとするものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a melanin production inhibitor and a whitening cosmetic, and more particularly, to a melanin production inhibitor which directly acts on a melanogenesis system of living pigment cells (melanocytes) to suppress melanin production, and storage. An object of the present invention is to provide a whitening cosmetic which has good stability at the time of use or use and is excellent in preventing and improving skin pigmentation.
【0002】[0002]
【従来の技術】シミ・ソバカスや日焼け後の色素沈着
は、皮膚内に存在する色素細胞の活性化によりメラニン
生成が著しく亢進したものであり、中高年令層の肌の悩
みの一つになっている。一般に、メラニンは色素細胞の
中で生合成された酵素チロジナーゼの働きによってチロ
シンからドーパ、ドーパからドーパキノンに変化し、次
いで5,6−ジヒドロキシインドール等の中間体を経て
形成されるものとされている。2. Description of the Related Art Spots and freckles and pigmentation after tanning are caused by the remarkable enhancement of melanin production due to the activation of pigment cells existing in the skin. I have. Generally, melanin is converted from tyrosine to dopa and dopa to dopaquinone by the action of the enzyme tyrosinase biosynthesized in pigment cells, and then formed via an intermediate such as 5,6-dihydroxyindole. .
【0003】従って、色黒の防止、改善にはメラニン生
成過程での活性阻害や既成メラニンの淡色漂白が必要で
あり、これに基づき従来から種々の美白成分が提案され
てきた。例えば、チロジナーゼ活性阻害に対してはグル
タチオンに代表される硫黄化合物が挙げられ、また淡色
漂白化に対しては、過酸化水素、ヒドロキノンやビタミ
ンC等が用いられてきた。[0003] Therefore, in order to prevent or improve the color darkness, it is necessary to inhibit the activity in the process of producing melanin or to bleach existing melanin in a light color. Based on this, various whitening components have been proposed. For example, sulfur compounds typified by glutathione are used for inhibiting tyrosinase activity, and hydrogen peroxide, hydroquinone, vitamin C and the like have been used for pale bleaching.
【0004】[0004]
【発明の解決しようとする課題】ところが、これら従来
の成分は処方系中での安定性が極めて悪く分解による着
色、異臭を生じたり、効果・効能の点からは細胞あるい
は生体レベルにおいては未だ不充分であった。また、ヒ
ドロキノンについては強い色白作用を有するものの非可
逆的白斑、かぶれを引き起こすなど安全性面で問題があ
る。このように、従来から用いられている成分は効能・
効果、安定性、安全性の点において真に実用的に満足で
きるものは得られていない。However, these conventional components have extremely poor stability in the formulation system, causing coloration and off-flavor due to decomposition, and are still unsatisfactory at the cellular or biological level in terms of their effects and efficacy. It was enough. Further, hydroquinone has a strong fairness effect, but has problems in safety, such as causing irreversible vitiligo and rash. In this way, the conventionally used ingredients are
No satisfactorily practically satisfactory effects, stability and safety have been obtained.
【0005】本発明はかかる実状に鑑みてなされたもの
であって、充分な皮膚色素沈着症の改善・治療等の薬理
効果を有し、かつ安全に使用できるメラニン生成抑制剤
及びこれを配合した美白化粧料を提供することを課題と
する。The present invention has been made in view of the above circumstances, and has a melanin production inhibitor which has a sufficient pharmacological effect such as improvement and treatment of skin pigmentation and can be used safely, and a compound comprising the same. It is an object to provide a whitening cosmetic.
【0006】[0006]
【課題を解決するための手段】本発明者らは、上記課題
を解決するため鋭意研究を重ねた結果、エスクリンが生
きた色素細胞のメラニン生成に対し強力な抑制効果を有
することを突き止め、更に、これを基剤中に一定濃度以
上で配合せしめた時に、皮膚に対する優れた色白効果を
発現することを見出し、これに基づき本発明を完成し
た。Means for Solving the Problems The present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that esculin has a strong inhibitory effect on melanin production of living pigment cells. It has been found that when this is mixed in a base at a certain concentration or more, an excellent fairness effect on the skin is exhibited, and the present invention has been completed based on this.
【0007】すなわち、本発明はエスクリンからなるメ
ラニン生成抑制剤およびこれを基剤全体に対し0.1〜
10重量%配合してなる美白化粧料に関するものであ
り、好ましい様態としては美白化粧料中に、更に紫外線
防御剤0.01〜5重量%を併用するか、または抗酸化
剤0.01〜5重量%を併用するか、または基剤のPH
を酸性域に調整するか、あるいはこれらを組み合わせる
ところの美白化粧料に関するものである。That is, the present invention relates to a melanin production inhibitor consisting of esculin and 0.1 to 10
The present invention relates to a whitening cosmetic containing 10% by weight, and is preferably used in combination with 0.01 to 5% by weight of an ultraviolet ray protective agent or 0.01 to 5% of an antioxidant in the whitening cosmetic. Weight% or the pH of the base
Whitening cosmetics in which is adjusted to an acidic region or a combination thereof.
【0008】以下、本発明を詳細に述べる。Hereinafter, the present invention will be described in detail.
【0009】本発明のメラニン生成抑制剤であるエスク
リンは、別名エスクレチン−6−β−グルコシドとも呼
ばれるクマリン配糖体の一つである。エスクリンについ
ては、天然界においてセイヨウトチノキ(マロニエ)や
トネリコの樹皮に含有されており、各種の単離法により
単離される白色、無臭の結晶であり、紫外線吸収能を有
するとともに、生理的には血管抵抗性の増強作用、リポ
キシゲナーゼ阻害活性をもつことが知られているが、こ
の物質が生きた色素細胞のメラニン生成抑制作用を有す
ることについては全く知られておらず、またこの物質の
色白効果を利用して実用的に美白化粧料に用いた例はな
かった。Esculin, which is a melanin production inhibitor of the present invention, is one of coumarin glycosides, also called esculetin-6-β-glucoside. Esculin is contained in the bark of horse chestnut (malonnier) and ash in the natural world, is a white, odorless crystal isolated by various isolation methods, and has ultraviolet absorbing ability. It is known to have vascular resistance enhancement and lipoxygenase inhibitory activity, but it is not known at all that this substance has a melanin production inhibitory effect on living pigment cells. There was no example of practical use for whitening cosmetics by using the same.
【0010】次に、本発明の美白化粧料では、上記エス
クリンを基剤全体に対し0.1〜10重量%の範囲で使
用する。この中でも、日焼けによるシミ、ソバカス、色
黒の憎悪の予防を目的として用いる場合は0.1重量%
以上が、また色素沈着症の改善を目的として用いる場合
は1重量%以上が有効量として使用できるものである。
0.1重量%より少ない量ではメラニン生成抑制作用に
基づく効果は期待できず、また10重量%を超える量を
用いても、効果にはほとんど変わりは見られないから配
合割合として10重量%を超える必要はない。特に好ま
しい量として0.5〜3重量%が選択される。Next, in the whitening cosmetic of the present invention, the above-mentioned esculin is used in a range of 0.1 to 10% by weight based on the whole base. Among them, 0.1% by weight when used for the purpose of preventing spots, freckles and hatred of sunburn due to sunburn.
As described above, when used for the purpose of improving pigmentation, 1% by weight or more can be used as an effective amount.
If the amount is less than 0.1% by weight, the effect based on the melanin production inhibitory effect cannot be expected. Even if an amount exceeding 10% by weight is used, the effect is hardly changed. There is no need to exceed. A particularly preferred amount is selected from 0.5 to 3% by weight.
【0011】尚、セイヨウトチノキエキスを日焼防止化
粧料や痔疾、うっ血の治療剤として利用することは旧来
より知られているが、市販、すなわち産業的に利用され
ているセイヨウトチノキエキス中のエスクリン含有率
は、せいぜい0.2重量%であるにすぎず、従って、仮
にセイヨウトチノキエキスを配合した薬剤にあっても、
その含有率は極めて微量であって実際的なメラニン生成
抑制効果は得られず、充分な色白効果は得られないもの
であった。そもそも植物抽出液であるセイヨウトチノキ
エキスには、エスクリンのほかにセイヨウトチノキエキ
スの著名な有効成分として知られるエスシンを始めとす
るサポニン類や夾雑物である色素を多量に含んでおり、
高濃度での配合は沈澱等の分離現象や着色などにより外
観を損ねるため、薬剤などに対する配合量が著しく制約
されざるを得ないのが実情である。The use of horse chestnut extract as a sunburn-preventing cosmetic, a remedy for hemorrhoids and congestion has been known for a long time, but the esculin contained in commercially available, that is, industrially used horse chestnut extract is used. The content is only 0.2% by weight at most, and therefore, even in the case of the medicine containing the horse chestnut extract,
The content was extremely small, and a practical melanin production inhibitory effect was not obtained, and a sufficient fairness effect was not obtained. In the first place, the horse chestnut extract, which is a plant extract, contains a large amount of saponins and other contaminant pigments, including escin, which is known as a prominent active ingredient of horse chestnut extract, in addition to esculin.
The compounding at a high concentration impairs the appearance due to separation phenomena such as sedimentation or coloring, so that the amount of the compounding agent for a drug or the like must be significantly restricted.
【0012】次に本発明の美白化粧料においては、前記
エスクリンと共に紫外線防御剤や抗酸化剤を併用する
か、または基剤のPHを酸性領域に調整するか、もしく
は乳化系においては油中水型の剤型とすることが好まし
い。すなわち、本発明者らの研究によると、エスクリン
を溶液または乳化物などの基剤中に前記配合範囲で配合
した場合、日光により一部分解・着色するということが
明らかとなった。そこで、さらに検討した結果、紫外線
防御剤を添加するか、抗酸化剤を添加するか、基剤のP
Hを酸性領域に調整するか、または乳化系においては油
中水型の基剤にするか、あるいはこれらの組合せによっ
てエスクリンを紫外線から安定に保てることが判明し
た。Next, in the whitening cosmetic of the present invention, an ultraviolet protective agent or an antioxidant is used in combination with the above-mentioned esculin, or the pH of the base is adjusted to an acidic range, or a water-in-oil It is preferred to use a dosage form of the type. That is, according to the study of the present inventors, it has been clarified that when esculin is blended in a base such as a solution or an emulsion in the above-mentioned blending range, it is partially decomposed and colored by sunlight. Therefore, as a result of further investigation, it was determined whether to add an ultraviolet protection agent, an antioxidant,
Esculin was found to be stable from ultraviolet light by adjusting H to the acidic region, or by using a water-in-oil base in emulsified systems, or a combination of these.
【0013】本発明に適用される紫外線防御剤とは、イ
ソフェルラ酸またはその塩、オキシベンゾンまたはその
誘導体、ジベンゾイルメタンまたはその誘導体、p−ア
ミノ安息香酸またはその誘導体、ケイ皮酸またはその誘
導体、ウロカニン酸またはその誘導体、酸化チタン、酸
化亜鉛等から選ばれる一種または二種以上であり、その
配合割合は基剤全体に対し0.01〜5重量%である。
好ましくは、4−(1,1−ジメチルエチル)−4’−
メトキシジベンゾイルメタンに代表されるジベンゾイル
メタン系や2−ヒドロキシ−4−メトキシベンゾフェノ
ンに代表されるオキシベンゾン系などのUV−A領域に
強い吸収をもつ紫外線吸収剤が選ばれる。The ultraviolet ray protective agent applied to the present invention includes: isoferulic acid or a salt thereof, oxybenzone or a derivative thereof, dibenzoylmethane or a derivative thereof, p-aminobenzoic acid or a derivative thereof, cinnamic acid or a derivative thereof, urocanin One or more selected from acids or derivatives thereof, titanium oxide, zinc oxide, and the like, and the compounding ratio is 0.01 to 5% by weight based on the entire base.
Preferably, 4- (1,1-dimethylethyl) -4′-
An ultraviolet absorber having a strong absorption in the UV-A region such as a dibenzoylmethane type represented by methoxydibenzoylmethane and an oxybenzone type represented by 2-hydroxy-4-methoxybenzophenone is selected.
【0014】本発明に適用される抗酸化剤とは、ブチル
ヒドロキシトルエン(BHT)、ブチルヒドロキシアニ
ソール(BHA)、トコフェロール類、アスコルビン酸
またはその誘導体等から選ばれる一種または二種以上で
あり、その配合割合は基剤全体に対し0.01〜5重量
%である。The antioxidant applied to the present invention is one or more selected from butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tocopherols, ascorbic acid or derivatives thereof, and the like. The mixing ratio is 0.01 to 5% by weight based on the whole base.
【0015】本発明に適用されるPH調整剤としてはク
エン酸緩衝液、リン酸緩衝液、酢酸緩衝液等が挙げら
れ、基剤のPHが酸性領域好ましくはPH4.0〜6.
5の範囲に調整される。Examples of the pH adjuster applied to the present invention include a citrate buffer, a phosphate buffer, an acetate buffer and the like. The pH of the base is in the acidic region, preferably pH 4.0 to 6.0.
It is adjusted to the range of 5.
【0016】また、本発明の美白化粧料には前述のエス
クリン、また併用剤としての紫外線防御剤、抗酸化剤、
PH調整剤の他に、化粧品に一般に用いられる各種成
分、すなわち水性成分、油性成分、粉末成分、界面活性
剤、保湿剤、増粘剤、色剤、香料、防腐剤、あるいは抗
炎症剤、エスクリン以外の美白成分等の薬剤を配合する
ことができる。更に、本発明の剤型は任意であり、従来
この種の美白化粧料に用いるものであればいずれでもよ
く、例えばクリーム、乳液、ローション、パック、浴用
剤等の剤型が挙げられる。Also, the whitening cosmetic of the present invention contains the above-mentioned esculin, and a sunscreen agent, an antioxidant,
In addition to the pH adjuster, various components generally used in cosmetics, that is, aqueous components, oil components, powder components, surfactants, humectants, thickeners, coloring agents, fragrances, preservatives, or anti-inflammatory agents, esculin Drugs such as whitening ingredients other than the above can be added. Further, the dosage form of the present invention is arbitrary, and any dosage form conventionally used in this type of whitening cosmetics may be used, and examples thereof include dosage forms such as creams, emulsions, lotions, packs, and bath preparations.
【0017】次に、本発明に係るエスクリンのメラニン
生成抑制剤としての有用性を評価するために行なった実
験および安定性に関して行なった各種実験について以下
に示す。Next, the experiments conducted to evaluate the usefulness of the esculin according to the present invention as a melanin production inhibitor and various experiments conducted for stability will be described below.
【0018】実験例1.色素細胞に対するメラニン生成
抑制作用 プラスチック培養フラスコ(75cm2)に5×104個
のB−16メラノーマ細胞を播種し、10%血清を含む
イーグルMEM培地で5%二酸化炭素、37℃条件下に
て培養した。2日後、エスクリンを培地中の濃度で5、
10、15μMとなるように添加し、さらに4日間培養
した。培養終了後、培地を除去し、平衡リン酸緩衝塩溶
液(PBS)で洗浄後、トリプシンおよびEDTA含有
溶液を使用して細胞を剥離させ、ガラス遠心管にあつめ
遠心分離により細胞を回収した。細胞を平衡リン酸緩衝
塩溶液で2回洗浄した後、沈渣に1N水酸化ナトリウム
を加え加熱溶解し、冷却後クロロホルムを加えて再び遠
心分離した。これによって得られた上清を400nmの
吸光度で測定し、予め合成メラニンを用いて作成した検
量線よりメラニン量を求めた。尚、メラニン量は106
個の細胞当りの 量として求めた。その結果を表1に示
す。Experimental Example 1 Inhibition of Melanin Production on Pigment Cells 5 × 10 4 B-16 melanoma cells were seeded in a plastic culture flask (75 cm 2 ), and cultured in an Eagle MEM medium containing 10% serum at 5% carbon dioxide at 37 ° C. Cultured. Two days later, esculin was added to the medium at a concentration of 5,
It was added to a concentration of 10, 15 μM, and the cells were further cultured for 4 days. After completion of the culture, the medium was removed, and the cells were washed with an equilibrated phosphate buffered saline (PBS). The cells were detached using a solution containing trypsin and EDTA, collected in a glass centrifuge tube, and collected by centrifugation. After the cells were washed twice with an equilibrated phosphate buffered saline solution, 1N sodium hydroxide was added to the sediment to dissolve by heating, and after cooling, chloroform was added and centrifuged again. The supernatant thus obtained was measured at an absorbance of 400 nm, and the amount of melanin was determined from a calibration curve previously prepared using synthetic melanin. The amount of melanin was 10 6
It was determined as the amount per individual cell. Table 1 shows the results.
【0019】[0019]
【表1】 [Table 1]
【0020】表1の結果から明らかなように、エスクリ
ンは色素細胞内のメラニン生成に対し顕著な抑制効果を
示すことが実証された。As is clear from the results in Table 1, it was demonstrated that esculin has a remarkable inhibitory effect on melanin production in pigment cells.
【0021】実験例2.紫外線による色素沈着抑制作用 茶色モルモット(7匹)の背部皮膚を電気バリカンとシ
ェバーで除毛した。次いで、1.5×1.5cmの照射
窓を左右対照に計6個もつ黒布で覆い、FL20S・E
30ランプを光源として1mW/cm2/sec.の紫
外線を4分20秒間照射した。この操作を1日1回の割
合で3日間連続して行った。照射終了翌日からプロピレ
ングリコール/エタノール(3:1)を溶媒として所定
量のエスクリン及び比較品として市販セイヨウトチノキ
エキスをそれぞれ溶解した試験溶液0.2mlを1日1
回、計10日間連続塗布した。対照には溶媒そのものを
用いた。実験開始14日目に処置部の色素沈着の程度を
下記の判定基準に従い肉眼観察により判定した。結果を
平均値として表2に示す。 (判定基準) 0:色素沈着を認めず 0.5:境界不明瞭な弱度の色素沈着 1.0:境界明瞭な軽度の色素沈着 2.0:境界明瞭な中等度の色素沈着 3.0:境界明瞭な強度の色素沈着Experimental Example 2 Inhibition of pigmentation by ultraviolet rays The back skin of brown guinea pigs (7 animals) was dehaired with an electric clipper and a shever. Next, the irradiation window of 1.5 × 1.5 cm was covered with a black cloth having a total of six for left and right contrast, and FL20S · E
1 mW / cm 2 / sec. For 4 minutes and 20 seconds. This operation was performed once a day for three consecutive days. From the day after the end of the irradiation, 0.2 ml of a test solution in which a predetermined amount of esculin was dissolved in propylene glycol / ethanol (3: 1) as a solvent and a commercially available horse chestnut extract as a comparative product were dissolved each day were used.
For 10 consecutive days. The solvent itself was used as a control. On the 14th day from the start of the experiment, the degree of pigmentation of the treated part was determined by visual observation according to the following criteria. The results are shown in Table 2 as average values. (Judgment criteria) 0: No pigmentation was observed 0.5: Weak pigmentation with indistinct boundaries 1.0: Mild pigmentation with distinct boundaries 2.0: Moderate pigmentation with distinct boundaries 3.0 : Pigmentation with clearly defined intensity
【0022】[0022]
【表2】 [Table 2]
【0023】表2の結果に示された如く、皮膚に塗布し
た場合のエスクリンは0.1%以上で紫外線によるメラ
ニン生成を明らかに抑制するが、セイヨウトチノキエキ
スでは実用的に配合可能な上限濃度、すなわち20%配
合においても満足すべき効果は認められなかった。As shown in the results in Table 2, when applied to the skin, esculin clearly inhibits melanin production by ultraviolet rays at 0.1% or more, but in the case of horse chestnut extract, the upper limit concentration which can be practically incorporated. That is, no satisfactory effect was observed even in the case of 20% blending.
【0024】実験例3.紫外線に対する安定性試験 エスクリンの0.5%溶液または1%配合軟膏を調整
し、紫外線に対する安定性を比較検討した。Experimental Example 3 Stability test for ultraviolet rays A 0.5% solution or a 1% ointment containing esculin was prepared, and the stability to ultraviolet rays was compared and examined.
【0025】(実験例3ー1)PH安定性 エスクリンの5%プロピレングリコール/エタノール
(3:1)溶液を、予め調整した各PHの0.1Mリン
酸緩衝液に1/10量添加して試験試料とした。これを
栓つきガラス試験管に3ml分取し、晴天の日に屋外に
1日放置した。実験終了後、溶液の色調を肉眼により評
価するとともにエスクリン残存率を高速液体クロマトグ
ラフィーにて測定した。リン酸緩衝液の作成に際して
は、PH5および6はHClで、PH8はNaOHにて
PHを調整した。その結果を表3−1に示す。(Experimental Example 3-1) PH stability A 5% propylene glycol / ethanol (3: 1) solution of esculin was added to a previously prepared 0.1 M phosphate buffer of each PH at 1/10 amount. A test sample was used. This was taken in a glass test tube with a stopper in an amount of 3 ml, and left outdoors for one day on a sunny day. After completion of the experiment, the color tone of the solution was visually evaluated, and the residual ratio of esculin was measured by high performance liquid chromatography. In preparing the phosphate buffer, PH5 and 6 were adjusted with HCl, and PH8 was adjusted with NaOH. The results are shown in Table 3-1.
【0026】[0026]
【表3−1】 [Table 3-1]
【0027】表3−1の結果に示されるようにエスクリ
ン水溶液は、PH7以上でのアルカリ領域では溶解直後
に黄色を呈し、更に日光照射に対して不安定であるのに
対し弱酸性から酸性域で安定に保たれることが判明し
た。As shown in the results of Table 3-1, the aqueous solution of esculin shows a yellow color immediately after dissolution in an alkaline region at pH 7 or higher and is unstable to sunlight irradiation, whereas it is unstable from sunlight to acidic region. It was found to be stable.
【0028】(実験例3-2)紫外線防御剤または抗酸
化剤の添加効果 エスクリンの5%プロピレングリコール/エタノール
(3:1)溶液を、50%エタノール水溶液に1/10
量添加して試験試料とした。更に、紫外線防御剤(4−
(1,1−ジメチルエチル)−4’−メトキシジベンゾ
イルメタン)あるいは抗酸化剤(ブチルヒドロキシトル
エン)を添加する場合はこれら物質の5%エタノール溶
液を作成後、1/5量加えた。これら試験液を栓つきガ
ラス試験管に3ml分取し、晴天の日に屋外に1日放置
した。実験終了後、溶液の色調を肉眼により評価すると
ともにエスクリン残存率を高速液体クロマトグラフィー
にて測定した。その結果を表3−2に示す。(Experimental Example 3-2) Effect of Addition of Ultraviolet Protecting Agent or Antioxidant A 5% propylene glycol / ethanol (3: 1) solution of esculin was added to 1/10 of a 50% aqueous ethanol solution.
A test sample was prepared by adding an amount. Furthermore, UV protection agents (4-
When (1,1-dimethylethyl) -4'-methoxydibenzoylmethane) or an antioxidant (butylhydroxytoluene) was added, a 5% ethanol solution of these substances was prepared, and then 1/5 was added. 3 ml of each of these test solutions was placed in a glass test tube with a stopper, and left outdoors for one day on a sunny day. After completion of the experiment, the color tone of the solution was visually evaluated, and the residual ratio of esculin was measured by high performance liquid chromatography. The results are shown in Table 3-2.
【0029】[0029]
【表3−2】 [Table 3-2]
【0030】表3−2に示されるように、エスクリンは
紫外線防御剤あるいは抗酸化剤の添加により着色と分解
が抑制されることが判明した。As shown in Table 3-2, it was found that coloring and decomposition of esculin were suppressed by the addition of an ultraviolet ray protective agent or an antioxidant.
【0031】(実験例3ー3)油中水(W/O)型乳化
系の効果 日本薬局方の吸水軟膏と親水軟膏にエスクリンを1%と
なるように練り込み、これを予め除毛したハートレー系
モルモットの背部皮膚に塗布し、ついでFL40S・B
LBランプを光源として4mW/cm2/sec.のエ
ネルギー強度で2時間照射した。実験終了後、皮膚表面
の着色の程度を肉眼評価した。その結果、親水軟膏では
黄色味を呈したが、油中水(W/O)型の吸水軟膏では
何ら変化は認められなかった。(Experimental example 3-3) Effect of water-in-oil (W / O) emulsifying system Esculin was kneaded into a water-absorbing ointment and a hydrophilic ointment of the Japanese Pharmacopoeia so as to be 1%, and the hair was removed beforehand. Hartley guinea pig applied to the back skin, then FL40S ・ B
Using an LB lamp as a light source, 4 mW / cm 2 / sec. Irradiation at an energy intensity of 2 hours. After completion of the experiment, the degree of coloring of the skin surface was visually evaluated. As a result, the hydrophilic ointment exhibited a yellow tint, but the water-in-oil (W / O) type water-absorbing ointment did not show any change.
【0032】実験例4.メラニン抑制効果の実使用テス
ト 後記実施例1に示す本発明品のクリームとエスクリンの
代わりに5%セイヨウトチノキエキスを配合した比較品
のクリームとを統計的に同等な40名の色黒、シミ、ソ
バカスに悩む女性集団に3ヶ月連用させ、メラニン抑制
効果を評価した。その結果を表4に示す。Experimental Example 4 Actual use test of melanin-suppressing effect The cream of the present invention shown in Example 1 to be described later and a cream of a comparative product containing 5% horse chestnut extract instead of esculin were statistically equivalent to 40 black and white spots, The female group suffering from freckles was continuously used for 3 months, and the melanin-suppressing effect was evaluated. Table 4 shows the results.
【0033】[0033]
【表4】 [Table 4]
【0034】表4の結果から明らかなように、エスクリ
ンを含む本発明品は5%セイヨウトチノキエキスを含む
比較品に対し格段に有効であることが証明された。尚、
本発明品塗布部位において皮膚に好ましくない反応は全
く観察されなかった。As is apparent from the results in Table 4, the product of the present invention containing esculin was proved to be significantly more effective than the comparative product containing 5% horse chestnut extract. still,
No undesired reactions on the skin were observed at the application site of the product of the present invention.
【0035】[0035]
【実施例】以下に本発明の実施例を示すが、本発明はこ
れらに制限されるものではない。尚、配合割合は重量部
である。EXAMPLES Examples of the present invention will be described below, but the present invention is not limited to these examples. The mixing ratio is part by weight.
【0036】実施例1.油中水型クリーム (A)スクワラン 12.0 ミツロウ 2.0 マイクロクリスタリンワックス 2.0 グリセリン(PO20)ピログルタミン酸モノパルミテート 5.0 4−(1,1−ジメチルエチル)−4’− メトキシジベンゾイルメタン 0.5 γ−トコフェロール 0.05 ブチルパラベン 0.2 (B)マルビット 8.0 1,3−ブタンジオール 7.0 エスクリン 2.0 精製水 61.25 (製法)(A)を80℃にて均一に溶解し、別に80℃
に溶解しておいた(B)をホモミキサーで撹拌しながら
(A)に添加して乳化後、30℃に冷却する。Embodiment 1 Water-in-oil cream (A) Squalane 12.0 Beeswax 2.0 Microcrystalline wax 2.0 Glycerin (PO20) Pyroglutamic acid monopalmitate 5.0 4- (1,1-Dimethylethyl) -4'-methoxydi Benzoylmethane 0.5 γ-Tocopherol 0.05 Butylparaben 0.2 (B) Marbit 8.0 1,3-butanediol 7.0 Esculin 2.0 Purified water 61.25 (Production method) (A) at 80 ° C. At 80 ℃
(A) is added to (A) while stirring with a homomixer and emulsified, and then cooled to 30 ° C.
【0037】実施例2.水中油型クリーム (A)POE(30)セチルエーテル 2.0 グリセリンモノステアレート 10.0 流動パラフィン 10.0 ワセリン 4.0 セタノール 5.0 γ−トコフェロール 0.05 BHT 0.01 2−ヒドロキシ−4−メトキシベンゾフェノン 0.5 ブチルパラベン 0.2 (B)プロピレングリコール 10.0 エスクリン 1.0 精製水 57.24 (製法)(A)の各成分を合わせ、80℃に加熱する。
(B)の各成分を合わせ、80℃に加熱する。(A)の
処方分を(B)の処方分を加えて撹拌乳化し、その後冷
却する。Embodiment 2 FIG. Oil-in-water cream (A) POE (30) cetyl ether 2.0 glycerin monostearate 10.0 liquid paraffin 10.0 vaseline 4.0 cetanol 5.0 γ-tocopherol 0.05 BHT 0.01 2-hydroxy- 4-methoxybenzophenone 0.5 butylparaben 0.2 (B) propylene glycol 10.0 esculin 1.0 Purified water 57.24 (Preparation method) Combine the components of (A) and heat to 80 ° C.
Combine the components of (B) and heat to 80 ° C. The formulation of (A) is added to the formulation of (B), and the mixture is emulsified with stirring, and then cooled.
【0038】実施例3.乳液 (A)合成ゲイロウ 2.5 セタノール 1.0 スクワラン 4.0 ステアリン酸 1.0 モノステアリン酸ポリエチレングリコール(25EO) 2.2 モノステアリン酸グリセリン 0.5 ブチルパラベン 0.1 γ−トコフェロール 0.05 BHT 0.01 4−(1,1−ジメチルエチル)−4’− メトキシジベンゾイルメタン 0.5 (B)1,3−ブチレングリコール 3.0 プロピレングリコール 7.0 キサンタンガム 0.1 カルボキシビニルポリマー 0.2 苛性カリ 0.2 エスクリン 1.0 精製水 76.64 (製法)(A)及び(B)を70℃で各々攪拌しながら
溶解する。(B)に(A)を加え予備乳化を行ないホモ
ミキサーで均一に乳化し、乳化後かき混ぜながら30℃
まで冷却する。Embodiment 3 FIG. Emulsion (A) Synthetic gay wax 2.5 Cetanol 1.0 Squalane 4.0 Stearic acid 1.0 Polyethylene glycol monostearate (25EO) 2.2 Glycerin monostearate 0.5 Butylparaben 0.1 γ-Tocopherol 05 BHT 0.01 4- (1,1-dimethylethyl) -4′-methoxydibenzoylmethane 0.5 (B) 1,3-butylene glycol 3.0 propylene glycol 7.0 Xanthan gum 0.1 Carboxyvinyl polymer 0.2 Caustic potash 0.2 Esculin 1.0 Purified water 76.64 (Preparation method) Dissolve (A) and (B) at 70 ° C. while stirring each. Add (A) to (B), pre-emulsify and homogenize uniformly with a homomixer. After emulsification, stir at 30 ° C.
Cool down to
【0039】実施例4.化粧水 (A)POE(20)ソルビタンモノラウリン酸エステル 1.5 POE(20)ラウリルエーテル 0.5 エタノール 10.0 γ−トコフェロール 0.02 (B)グリセリン 5.0 プロピレングリコール 4.0 クエン酸 0.15 クエン酸ナトリウム 0.1 エスクリン 0.5 精製水 78.23 (製法)(A)の各成分を合わせ、室温下に溶解する。
一方、(B)の各成分も室温下に溶解し、これを(A)
処方分に加えて可溶化する。Embodiment 4 FIG. Lotion (A) POE (20) sorbitan monolaurate 1.5 POE (20) lauryl ether 0.5 ethanol 10.0 γ-tocopherol 0.02 (B) glycerin 5.0 propylene glycol 4.0 citric acid 0 .15 Sodium citrate 0.1 Esculin 0.5 Purified water 78.23 (Production method) Combine the components of (A) and dissolve at room temperature.
On the other hand, each component of (B) was also dissolved at room temperature, and this was dissolved in (A)
Solubilize in addition to prescription.
【0040】実施例5.パック料 (A)ポリビニルアルコール 15.0 精製水 40.0 (B)ビサボロール 0.5 γ−トコフェロール 0.02 エタノール 4.0 1,3−ブチレングリコール 4.0 ポリオキシエチレン(8)ポリオキシ プロピレングリコール(55) 3.0 精製水 32.98 エスクリン 0.5 (製法)(A)を室温にて分散溶解する。これに(B)
を加えて均一に溶解する。Embodiment 5 FIG. Packing charge (A) Polyvinyl alcohol 15.0 Purified water 40.0 (B) Bisabolol 0.5 γ-Tocopherol 0.02 Ethanol 4.0 1,3-butylene glycol 4.0 Polyoxyethylene (8) Polyoxypropylene glycol (55) 3.0 Purified water 32.98 Esculin 0.5 (Production method) (A) is dispersed and dissolved at room temperature. To this (B)
And dissolve uniformly.
【0041】[0041]
【発明の効果】本発明によれば、エスクリンは生きた色
素細胞に対し強いメラニン生成抑制作用を発揮し、これ
を基剤中に一定割合以上配合せしめたとき皮膚に対する
格段に優れた色白効果をもたらすことから、シミ、ソバ
カス、日焼けによる色黒等の局所性並びにアジソン病等
の全身性色素沈着症の改善・治療用に利用できる。しか
も、安全性にも優れるため長期連用使用が可能である。According to the present invention, esculin exerts a strong melanin production inhibitory effect on living pigment cells, and when incorporated into a base at a certain ratio or more, esculin has a remarkably excellent skin-whitening effect on the skin. It can be used for the improvement and treatment of local pigmentation such as spots, freckles and sunburn, and systemic pigmentation such as Addison's disease. Moreover, it is excellent in safety and can be used continuously for a long time.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 7/42 A61K 7/42 9/06 9/06 G 31/00 643 31/00 643D 31/70 31/70 // C07H 17/075 C07H 17/075 (72)発明者 片桐 崇行 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社 横浜研究所 内 (72)発明者 横山 浩治 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社 横浜研究所 内 (72)発明者 大貫 敬子 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社 横浜研究所 内 (72)発明者 中野 博行 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社 横浜研究所 内 (56)参考文献 特開 昭52−105221(JP,A) 特開 昭63−303919(JP,A) 特公 昭48−5022(JP,B1) (58)調査した分野(Int.Cl.6,DB名) A61K 7/48 A61K 7/00 A61K 7/42 A61K 9/06 C07H 17/075 ────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 7/42 A61K 7/42 9/06 9/06 G 31/00 643 31/00 643D 31/70 31/70 // C07H 17/075 C07H 17/075 (72) Inventor Takayuki Katagiri 27-1 Takashimadai, Kanagawa-ku, Kanagawa-ku, Yokohama-shi, Kanagawa Prefecture Inside the Yokohama Research Laboratory (72) Inventor Koji Yokoyama 27, Takashimadai, Kanagawa-ku, Yokohama-shi, Kanagawa No. 1 Pola Kasei Kogyo Co., Ltd., Yokohama Research Center (72) Inventor Keiko Onuki 27-1, Takashimadai, Kanagawa-ku, Kanagawa-ku, Kanagawa Prefecture Pola Kasei Kogyo Co., Ltd. Yokohama Research Center (72) Inventor Hiroyuki Nakano Kanagawa, Kanagawa Prefecture 27-1 Takashima-ku, Ward POLA CHEMICAL INDUSTRIES, LTD. Yokohama Research Laboratory (56) Reference JP-A-52-105221 (JP, A) JP-A-63-303919 (JP, A) JP-B-48-5022 (JP, B1) (58) Fields investigated (Int. Cl. 6 , DB name) A61K 7/48 A61K 7/00 A61K 7/42 A61K 9/06 C07H 17/075
Claims (5)
剤。1. A melanin production inhibitor comprising esculin.
を基剤全体に対し0.1〜10重量%配合することを特
徴とする美白化粧料。2. A whitening cosmetic comprising a melanin production inhibitor comprising esculin in an amount of 0.1 to 10% by weight based on the whole base.
請求項2に記載の美白化粧料。3. The whitening cosmetic according to claim 2, comprising 0.01 to 5% by weight of an ultraviolet ray protective agent.
項2または3の何れかに記載の美白化粧料。4. The whitening cosmetic according to claim 2, comprising 0.01 to 5% by weight of an antioxidant.
ある請求項2乃至4の何れかに記載の美白化粧料。5. The whitening cosmetic according to claim 2, wherein the pH of the base is adjusted to an acidic range.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3181832A JP2986966B2 (en) | 1991-06-26 | 1991-06-26 | Melanin production inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3181832A JP2986966B2 (en) | 1991-06-26 | 1991-06-26 | Melanin production inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05934A JPH05934A (en) | 1993-01-08 |
| JP2986966B2 true JP2986966B2 (en) | 1999-12-06 |
Family
ID=16107602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3181832A Expired - Lifetime JP2986966B2 (en) | 1991-06-26 | 1991-06-26 | Melanin production inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2986966B2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3615557B2 (en) * | 1993-09-07 | 2005-02-02 | 株式会社資生堂 | Anti-pigmentation agent |
| JP3359774B2 (en) * | 1994-07-07 | 2002-12-24 | 株式会社資生堂 | External preparation for skin |
| FR2747038B1 (en) * | 1996-04-05 | 1998-05-22 | Oreal | PHOTOSTABLE FILTERING COMPOSITION COMPRISING A DIBENZOYLMETHANE DERIVATIVE AND A POLYSACCHARIDE ALKYLETHER AND USES THEREOF |
| JP3633822B2 (en) * | 1999-03-23 | 2005-03-30 | ポーラ化成工業株式会社 | Protective cosmetic |
| KR20010094548A (en) * | 2000-03-31 | 2001-11-01 | 유상옥,송운한 | Skin Care Cosmetic Composition |
| JP2003113101A (en) * | 2001-09-28 | 2003-04-18 | Saitama Daiichi Seiyaku Kk | Method for preventing discoloration and water-borne cataplasm containing discoloration inhibitor |
| JP4387639B2 (en) * | 2002-07-16 | 2009-12-16 | 久光製薬株式会社 | Transdermal absorption preparation |
| WO2004080432A1 (en) * | 2003-03-10 | 2004-09-23 | Songwoo Kim | Composition for lip cosmetics |
| JP4136997B2 (en) * | 2004-04-26 | 2008-08-20 | ポーラ化成工業株式会社 | Skin preparation for summer |
-
1991
- 1991-06-26 JP JP3181832A patent/JP2986966B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05934A (en) | 1993-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4970216A (en) | Skin treatment composition and method | |
| EP0238302B1 (en) | Skin treatment composition | |
| JPH05306231A (en) | Skin external preparation | |
| JP2986966B2 (en) | Melanin production inhibitor | |
| JPH11315008A (en) | Antiaging agent | |
| JP2787404B2 (en) | External preparation for skin | |
| JP2829690B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JPH11349435A (en) | External preparation for skin effective for preventing and improving pigmentation symptoms caused by ultraviolet rays | |
| JP3236130B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JPH0925209A (en) | Skin preparation for external use | |
| JP3140876B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JPS61215311A (en) | External agent for skin | |
| JPH09124474A (en) | Suppressant for melanogenesis and dermal preparation for external use | |
| JPH09132527A (en) | Suppressant for melanogenesis and dermal preparation for external use | |
| JPH11106347A (en) | Immunoactivator | |
| JPH0977660A (en) | Melanogenesis suppressing agent and skin preparation for external use | |
| JP3192499B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JP2886222B2 (en) | External preparation for anti-pigmentation | |
| JPH11180854A (en) | External preparation for skin | |
| JP3195834B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JPH0558872A (en) | Skin medicine for external use | |
| JP2931714B2 (en) | External preparation for skin | |
| JP2999621B2 (en) | External preparation for skin | |
| JP3195835B2 (en) | Melanin production inhibitor and external preparation for skin | |
| JPH07206654A (en) | Melanogenesis suppressor and skin external preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111001 Year of fee payment: 12 |